The firm said it will develop a test for use at home and at the point of care to aid the diagnosis of syphilis and distinguish between active and past infections.

Growth for the firm's core lab and pathology lab businesses was offset by a decline in molecular diagnostics and near patient care in the first nine months of the year.

Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.

The Houston-based firm is set to scale up its Flu/Covid test manufacturing for the current respiratory virus season.

NEW YORK – The Advanced Research Projects Agency for Health (ARPA-H) announced on Wednesday $110 million in awards given to 23 commercial and academic entities as part of its Sprint for Women's Health ...

NEW YORK – Roche on Wednesday announced that for the first nine months of 2024 its diagnostics division revenues were essentially flat at CHF 10.73 billion ($12.36 billion) compared to CHF 10.68 ...

NEW YORK – Owlstone Medical has been developing a menu of breath-based tests using parallel approaches to detect in breath endogenous biomarkers of disease and measuring signals produced as the body ...

NEW YORK – Danaher reported a 3 percent year-over-year increase in third quarter revenues on Tuesday even as the firm reported softness in China for its life sciences and diagnostics segments..

The Maryland-based firm said that the money will support the development and commercialization of a screening test for esophageal squamous cell carcinoma.

CEO Jim Davis said the company is on track to close eight lab acquisition deals this year, though he added that it is now in an "integration and digestion" phase.

The company reported revenues of $2.49 billion, up from $2.30 billion in the year-ago period and above the consensus Wall Street estimate of $2.42 billion.

NEW YORK – After receiving 510 (k) clearance early this month from the US Food and Drug Administration for its sepsis test, Swiss diagnostics company Abionic is targeting the US for further ...